Literature DB >> 35362874

Clinical and radiological findings of glioblastomas harboring a BRAF V600E mutation.

Yukitomo Ishi1, Shigeru Yamaguchi2, Michinari Okamoto1, Ryosuke Sawaya1, Shogo Endo3, Hiroaki Motegi1, Shunsuke Terasaka4, Zen-Ichi Tanei5, Kanako C Hatanaka6, Shinya Tanaka5,7, Miki Fujimura1.   

Abstract

The aim of this study was to analyze the clinical and radiological characteristics of glioblastomas (GBMs) harboring a BRAF mutation. Sequencing analysis of BRAF, IDH1/2, and TERT promoters was performed on GBM samples of patients older than 15 years. The clinical, pathological, and radiological data of patients were retrospectively reviewed. Patients were classified into three groups according to their BRAF and IDH1/2 status: BRAF group, IDH group, and BRAF/IDH-wild-type (WT) group. Among 179 GBM cases, we identified nine cases with a BRAF mutation and nine with IDH mutation. The WT group had 161 cases. Age at onset in the BRAF group was significantly lower compared to the WT group and was similar to the IDH group. In cases with negative IDH1-R132H staining and age < 55 years, 15.2% were BRAF-mutant cases. Similar to the IDH group, overall survival of the BRAF group was significantly longer compared with the WT group. Among nine cases in the BRAF group, three cases had hemorrhagic onset and prior lesions were observed in two cases. In conclusion, age < 55 years, being IDH1-R132H negative, with hemorrhagic onset or the presence of prior lesions are factors that signal recommendation of BRAF analysis for adult GBM patients.
© 2022. The Author(s), under exclusive licence to The Japan Society of Brain Tumor Pathology.

Entities:  

Keywords:  BRAF V600E; Glioblastoma; IDH1/2; MRI

Mesh:

Substances:

Year:  2022        PMID: 35362874     DOI: 10.1007/s10014-022-00432-7

Source DB:  PubMed          Journal:  Brain Tumor Pathol        ISSN: 1433-7398            Impact factor:   3.298


  8 in total

1.  Prognostic role of H3K27M mutation, histone H3K27 methylation status, and EZH2 expression in diffuse spinal cord gliomas.

Authors:  Yukitomo Ishi; Soichiro Takamiya; Toshitaka Seki; Kazuyoshi Yamazaki; Kazutoshi Hida; Kanako C Hatanaka; Yusuke Ishida; Yoshitaka Oda; Shinya Tanaka; Shigeru Yamaguchi
Journal:  Brain Tumor Pathol       Date:  2020-06-11       Impact factor: 3.298

2.  Systemic immune-inflammation index predicts the outcome after aneurysmal subarachnoid hemorrhage.

Authors:  Fushu Luo; Yuanyou Li; Yutong Zhao; Mingjiang Sun; Qiuguang He; Rong Wen; Zongyi Xie
Journal:  Neurosurg Rev       Date:  2021-10-31       Impact factor: 3.042

3.  Response to letter to the editor by Moudgil-Joshi and Kaliaperumal.

Authors:  David N Louis; Ian A Cree
Journal:  Neuro Oncol       Date:  2021-12-01       Impact factor: 13.029

4.  BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity.

Authors:  Nozomi Nakajima; Sumihito Nobusawa; Satoshi Nakata; Mitsutoshi Nakada; Tatsuya Yamazaki; Nozomi Matsumura; Kenichi Harada; Hadzki Matsuda; Nobuaki Funata; Shoichi Nagai; Hideo Nakamura; Atsushi Sasaki; Jiro Akimoto; Junko Hirato; Hideaki Yokoo
Journal:  Brain Pathol       Date:  2017-12-05       Impact factor: 6.508

5.  Epithelioid/rhabdoid glioblastoma: a highly aggressive subtype of glioblastoma.

Authors:  Kazutaka Sugimoto; Makoto Ideguchi; Tokuhiro Kimura; Koji Kajiwara; Hirochika Imoto; Hirokazu Sadahiro; Aya Ishii; Hiroo Kawano; Eiji Ikeda; Michiyasu Suzuki
Journal:  Brain Tumor Pathol       Date:  2015-12-14       Impact factor: 3.298

6.  Predicting BRAF V600E mutation in glioblastoma: utility of radiographic features.

Authors:  Manabu Natsumeda; Michael Chang; Ramil Gabdulkhaev; Haruhiko Takahashi; Yoshihiro Tsukamoto; Yu Kanemaru; Masayasu Okada; Makoto Oishi; Kouichirou Okamoto; Fausto J Rodriguez; Akiyoshi Kakita; Yukihiko Fujii; Karisa C Schreck
Journal:  Brain Tumor Pathol       Date:  2021-07-03       Impact factor: 3.298

7.  Circular RNA circ_ASAP2 regulates drug sensitivity and functional behaviors of cisplatin-resistant gastric cancer cells by the miR-330-3p/NT5E axis.

Authors:  Yongjun Sun; Jie Ma; Junkai Lin; Dawei Sun; Ping Song; Lujing Shi; Hongtao Li; Ruijie Wang; Ziwen Wang; Shijun Liu
Journal:  Anticancer Drugs       Date:  2021-10-01       Impact factor: 2.248

Review 8.  Response to BRAF and MEK1/2 inhibition in a young adult with BRAF V600E mutant epithelioid glioblastoma multiforme: A Case Report and Literature Review.

Authors:  Ashwin Venkatesh; Amol Joshi; Kieren Allinson; Tilak Das; Thomas Santarius; Sarah J Jefferies; Fiona P Harris; Rajesh Jena; Gary J Doherty
Journal:  Curr Probl Cancer       Date:  2021-01-12       Impact factor: 3.187

  8 in total
  2 in total

1.  Prediction of BRAF mutation status in glioblastoma multiforme by preoperative ring enhancement appearances on MRI.

Authors:  Xiaomin Cai; Zheng Chen; Bowen Chang; Ming Tu; Shiting Li; Xuhui Wang; Ming Chen
Journal:  Front Oncol       Date:  2022-08-08       Impact factor: 5.738

Review 2.  Imaging of GBM in the Age of Molecular Markers and MRI Guided Adaptive Radiation Therapy.

Authors:  Salah Dajani; Virginia B Hill; John A Kalapurakal; Craig M Horbinski; Eric G Nesbit; Sean Sachdev; Amulya Yalamanchili; Tarita O Thomas
Journal:  J Clin Med       Date:  2022-10-10       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.